InsiderTrades.com logo

THAR Insider Trading

Insider Ownership Percentage: 6.70%
Insider Buying (Last 12 Months): $592,464.32
Insider Selling (Last 12 Months): $0.00

Tharimmune Insider Trading History Chart

This chart shows the insider buying and selling history at Tharimmune by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Tharimmune Share Price & Price History

Current Price: $4.89
Price Change: ▲ Price Increase of +0.21 (4.49%)
As of 02/23/2026 01:00 AM ET

This chart shows the closing price history over time for THAR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Tharimmune Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/20/2025Gravitas Capital LpChairmanBuy337,838$1.48$500,000.24732,424View SEC Filing Icon  
6/20/2025Sanam ParikhDirectorBuy1,000$1.45$1,450.001,770View SEC Filing Icon  
6/20/2025Sireesh AppajosyulaCEOBuy61,496$1.48$91,014.0864,868View SEC Filing Icon  
12/19/2024Randy MilbyCEOBuy4,600$2.12$9,752.0017,534View SEC Filing Icon  
11/13/2024Sireesh AppajosyulaCOOBuy5,000$2.02$10,100.0010,758View SEC Filing Icon  
10/8/2024Randy MilbyCEOBuy2,500$2.09$5,225.0012,934View SEC Filing Icon  
10/8/2024Sireesh AppajosyulaCOOBuy5,000$1.93$9,650.0016,364View SEC Filing Icon  
12/15/2023Randy MilbyCEOBuy1,933$7.50$14,497.5010,434View SEC Filing Icon  
11/30/2023Randy MilbyCEOBuy666$15.00$9,990.008,501View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Tharimmune (NASDAQ:THAR)

1.16% of Tharimmune stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at THAR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Tharimmune Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/18/2026Feynman Point Asset Management LLC433,604$1.31M1.8%N/A1.149%Search for SEC Filing on Google Icon
2/17/2026Blair William & Co. IL274,324$0.83M0.0%N/A0.727%Search for SEC Filing on Google Icon
2/16/2026Clear Street Group Inc.1,671,836$5.07M0.0%N/A4.431%Search for SEC Filing on Google Icon
2/13/2026Marshall Wace LLP339,789$1.03M0.0%N/A0.901%Search for SEC Filing on Google Icon
2/13/2026State Street Corp36,621$0.11M0.0%+109.0%0.097%Search for SEC Filing on Google Icon
2/12/2026Aristides Capital LLC83,500$0.25M0.0%N/A0.221%Search for SEC Filing on Google Icon
2/11/2026ARK Investment Management LLC3,252,033$9.85M0.1%N/A8.619%Search for SEC Filing on Google Icon
2/9/2026Geode Capital Management LLC335,923$1.02M0.0%+1,102.6%0.890%Search for SEC Filing on Google Icon
2/3/2026Drucker Wealth 3.0 LLC25,337$77K0.0%+150.0%0.067%Search for SEC Filing on Google Icon
1/20/2026Essex LLC10,155$31K0.0%N/A0.027%Search for SEC Filing on Google Icon
11/13/2025Franklin Resources Inc.25,000$71K0.0%-44.4%0.329%Search for SEC Filing on Google Icon
11/7/2025Drucker Wealth 3.0 LLC10,135$29K0.0%N/A0.133%Search for SEC Filing on Google Icon
8/12/2025XTX Topco Ltd12,911$25K0.0%N/A0.306%Search for SEC Filing on Google Icon
8/12/2025Franklin Resources Inc.45,000$88K0.0%N/A1.066%Search for SEC Filing on Google Icon
2/11/2025Virtu Financial LLC21,371$44K0.0%N/A1.107%Search for SEC Filing on Google Icon
11/6/2024Curi RMB Capital LLC23,620$59K0.0%N/A2.056%Search for SEC Filing on Google Icon
5/12/2022Murchinson Ltd.116,029$0.19M0.0%N/A1.021%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Tharimmune logo
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
Read More on Tharimmune

Today's Range

Now: $4.89
Low: $4.44
High: $5.07

50 Day Range

MA: $3.52
Low: $2.22
High: $5.48

52 Week Range

Now: $4.89
Low: $0.95
High: $9.08

Volume

921,275 shs

Average Volume

1,476,877 shs

Market Capitalization

$184.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.43

Who are the company insiders with the largest holdings of Tharimmune?

Tharimmune's top insider shareholders include:
  1. Gravitas Capital Lp (Chairman)
  2. Sireesh Appajosyula (CEO)
  3. Randy Milby (CEO)
  4. Sireesh Appajosyula (COO)
  5. Sanam Parikh (Director)
Learn More about top insider investors at Tharimmune.

Who are the major institutional investors of Tharimmune?

Tharimmune's top institutional shareholders include:
  1. ARK Investment Management LLC — 8.62%
  2. Clear Street Group Inc. — 4.43%
  3. Feynman Point Asset Management LLC — 1.15%
  4. Marshall Wace LLP — 0.90%
  5. Geode Capital Management LLC — 0.89%
  6. Blair William & Co. IL — 0.73%
Learn More about top institutional investors of Tharimmune stock.

Which major investors are buying Tharimmune stock?

During the last quarter, THAR stock was bought by institutional investors including:
  1. ARK Investment Management LLC
  2. Clear Street Group Inc.
  3. Feynman Point Asset Management LLC
  4. Marshall Wace LLP
  5. Geode Capital Management LLC
  6. Blair William & Co. IL
  7. Aristides Capital LLC
  8. State Street Corp
Within the last year, these company insiders have bought Tharimmune stock:
  1. Gravitas Capital Lp (Chairman)
  2. Sireesh Appajosyula (CEO)
  3. Randy Milby (CEO)
  4. Sireesh Appajosyula (COO)
  5. Sanam Parikh (Director)
Learn More investors buying Tharimmune stock.